Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study

  • Kim, Minseok Albert
  • Kim, Seung Up
  • Sinn, Dong Hyun
  • Jang, Jeong Won
  • Lim, Young-Suk
  • ... Lee, Han Ah
  • 외 25명
Citations

WEB OF SCIENCE

32
Citations

SCOPUS

37

초록

Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. Designs This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). Results During follow-up (median=26.9 months, IQR=12.2–49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). Conclusion The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA.

키워드

antiviralsHBsAgHBV DNA redetectionhepatocellular carcinomaCHRONIC HEPATITIS-BHEPATOCELLULAR-CARCINOMAENTECAVIR THERAPYSURFACE-ANTIGENREDUCED RISKVIRUSRESISTANCEREDUCTION
제목
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
저자
Kim, Minseok AlbertKim, Seung UpSinn, Dong HyunJang, Jeong WonLim, Young-SukAhn, Sang HoonShim, Jae-JunSeo, Yeon SeokBaek, Yang HyunKim, Sang GyuneKim, Young SeokKim, Ji HoonChoe, Won HyeokYim, Hyung JoonLee, Hyun WoongKwon, Jung HyunLee, Sung WonJang, Jae YoungKim, Hwi YoungPark, YewanKim, Gi-AeYang, HyunLee, Han AhKoh, MyeongseokLee, Young-SunKim, MinkooChang, YoungKim, Yoon JunYoon, Jung-HwanZoulim, FabienLee, Jeong-Hoon
DOI
10.1136/gutjnl-2019-320015
발행일
2020-12
유형
Article
저널명
Gut
69
12
페이지
2214 ~ 2222